CG Oncology (NASDAQ:CGON) Reaches New 1-Year High – Should You Buy?

Shares of CG Oncology, Inc. (NASDAQ:CGON – Get Free Report) reached a new 52-week high during trading on Monday. The stock traded as high as $99.00 and last traded at $89.78, with a volume of 372,391 shares changing hands. The stock had previously closed at $74.40.

Analyst Ratings Changes

A number of research analysts recently commented on CGON shares. Wedbush upped their price objective on CG Oncology from $80.00 to $84.00 and gave the company an “outperform” rating in a report on Friday, November 6th. Truist Financial raised their target price on CG Oncology from $82.00 to $85.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Royal Bank Of Canada reduced their target price on CG Oncology from $81.00 to $79.00 and set an “outperform” rating on the stock in a research report on Friday, August 7th. Guggenheim reduced their target price on CG Oncology from $90.00 to $89.00 and set a “buy” rating on the stock in a research report on Monday, November 9th. Finally, Piper Sandler upped their price target on CG Oncology from $82.00 to $85.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $88.11.

Get Our Latest Report on CG Oncology

CG Oncology Stock Performance

The company has a 50 day moving average of $68.04 and a 200 day moving average of $66.54. The stock has a market capitalization of $7.43 billion, a price-to-earnings ratio of -28.85 and a beta of 0.35.

CG Oncology (NASDAQ:CGON – Get Free Report) last issued its earnings results on Friday, November 6th. The company reported ($0.64) earnings per share for the quarter, beating the consensus estimate of ($0.83) by $0.19. CG Oncology had a negative net margin of 3,851.09% and a negative return on equity of 24.58%. The firm had revenue of $1.60 million for the quarter, compared to analysts’ expectations of $0.55 million. As a group, research analysts expect that CG Oncology, Inc. will post -3.00 EPS for the current fiscal year.

Insider Activity at CG Oncology

In related news, Director Leonard E. Post sold 1,000 shares of the stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $62.06, for a total value of $62,060.00. Following the transaction, the director owned 1,000 shares of the company’s stock, valued at $62,060. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 4.80% of the company’s stock.

Hedge Funds Weigh In On CG Oncology

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Jump Financial LLC purchased a new position in shares of CG Oncology during the third quarter worth about $4,665,000. Marshall Wace LLP increased its stake in CG Oncology by 179.8% in the third quarter. Marshall Wace LLP now owns 11,708 shares of the company’s stock valued at $830,000 after purchasing an additional 7,523 shares during the period. Empowered Funds LLC acquired a new position in CG Oncology in the third quarter valued at $201,000. First Trust Advisors LP increased its stake in CG Oncology by 17.0% in the third quarter. First Trust Advisors LP now owns 273,284 shares of the company’s stock valued at $19,373,000 after purchasing an additional 39,767 shares during the period. Finally, Public Sector Pension Investment Board acquired a new position in CG Oncology in the third quarter valued at $12,902,000. 26.56% of the stock is owned by institutional investors and hedge funds.

CG Oncology Company Profile

(Get Free Report)

CG Oncology is a clinical-stage biotechnology company focused on developing treatments for bladder cancer. Based in Irvine, California, the company’s research centers on therapies delivered directly into the bladder. Its lead investigational therapy, cretostimogene grenadenorepvec (formerly CG0070), is an oncolytic immunotherapy being developed for non-muscle-invasive bladder cancer, including disease that has not responded to Bacillus Calmette-Guérin (BCG) treatment. The modified virus is designed to target cancer cells and stimulate an immune response.

Recommended Stories

Receive News & Ratings for CG Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CG Oncology and related companies with MarketBeat.com's FREE daily email newsletter.